Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03038646
Other study ID # MIN-101C06
Secondary ID
Status Completed
Phase Phase 1
First received January 10, 2017
Last updated August 30, 2017
Start date November 30, 2016
Est. completion date April 20, 2017

Study information

Verified date August 2017
Source Minerva Neurosciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

- To evaluate the pharmacokinetic (PK) profiles of MIN-l0l following administration of modified release (MR) formulations of MIN-l0l in healthy male and female subjects

- To select 1 MR formulation for use in fed state

- To evaluate the effect of food on the bioavailability of MIN-l0l selected MR formulation


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date April 20, 2017
Est. primary completion date April 20, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria:

1. Confirmed CYP 2D6 extensive metaboliser genotype

2. Subject has given voluntary written informed consent before performance of any study related procedure

3. Must be 18 to 45 years of age, inclusive

4. Subject must be a healthy male or female as indicated by the protocol

5. Agree to abstain from all medication (except for allowed birth control for 21 days before the first dose with MIN-101

6. Subject agrees to use the methods of birth control as outlined in the protocol

7. Must be willing and able to communicate and participate in the whole study.

8. Willing to eat all the food supplied throughout the study.

Exclusion Criteria:

1. A history of clinically significant gastrointestinal disease, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic or psychiatric disease or any other condition which, in the opinion of the principle investigator, would jeopardize the safety of the subject or impact the validity of the study results

2. Acute diarrhoea or constipation in the 7 days before the predicted first study day.

3. Subject has donated blood within 90 days or plasma within 30 days of study dosing

4. Regular alcohol consumption in males> 21 units per week and Females > 14 units per week (1 Unit = 1/2 pint beer, 25 mL of 40or a 125 mL glass of wine)

5. Subject has a borderline or long QTc Fridericia interval as defined by screening readings of >430 msec for males and >440 for females or a personal or familial history of long QT syndrome

6. Subject has participated in a clinical trial within 90 days prior to study initiation

7. Females who are pregnant or breast feeding

8. Subject has used any prescription medication or over-the-counter (OTC) medication, including vitamin supplements, within 21 days prior to day l

9. Subject has been treated with any known P450 206 or 3A4 enzymes altering drugs within 30 days prior to the study

10. Subject has smoked or used nicotine products within 2 months prior to or during the study

11. Subject has sought advice from or been referred to a GP or counsellor for abuse or misuse of alcohol, non-medical drugs, medicinal drugs or other substance abuse, e.g. solvents

12. Subject has a positive blood screen for HIV, Hepatitis B surface antigen (HBsAg), and Hepatitis C Antibody

13. Any current or previous use of drugs such as opiates, cocaine, ecstasy, or intravenous amphetamines and/or a positive urine screen for alcohol or drugs of abuse. Subjects who admit to occasional past use of cannabis will not be excluded as long as they have a negative drugs-of-abuse test and have been abstinent from cannabis use for at least 3 months

14. Subject has a current uncontrolled inter-current illness (i.e., active infection) or has had a clinically significant illness within the last 30 days prior to Day 1

15. Subject has had major surgery within 28 days of study entry, or 12 months prior to study for gastrointestinal surgery.

16. Failure to satisfy the investigator of fitness to participate for any other reason.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MIN-101


Locations

Country Name City State
Ireland Biokinetic Europe Belfast

Sponsors (1)

Lead Sponsor Collaborator
Minerva Neurosciences

Country where clinical trial is conducted

Ireland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1: Plasma PK parameter, Cmax To estimate the relative bioavailability of MIN-l0l following MIN-101 administration. Plasma samples will be analyzed for MIN-101 and its metabolites using a validated LC-MS/MS method from predose up to 72 hours post dose: Blood samples for MIN-101 will be collected at time 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 48, 60, and 72 hours post-dose on Day 1 of all periods.
Primary Part 1: Plasma PK parameter, Tmax from predose up to 72 hours post dose
Primary Part 1: Plasma PK parameter, Tlag from predose up to 72 hours post dose
Primary Part 1: Plasma PK parameter,partial AUC (e.g., AUC12, AUC24), AUClast, AUC8 from predose up to 72 hours post dose
Primary Part 1: Plasma PK parameter, ?z and t1/2 from predose up to 72 hours post dose
Primary Part 2: Plasma PK parameter, Cmax To estimate the relative bioavailability of MIN-101 and its main metabolites following the administration of the selected modified release formulation in different food conditions (fasted or fed state). from predose up to 72 hours post dose: Blood samples for MIN-101 will be collected at time 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 48, 60, and 72 hours post-dose on Day 1 of all periods.
Primary Part 2: Plasma PK parameter, Tmax from predose up to 72 hours post dose
Primary Part 2: Plasma PK parameter, Tlag from predose up to 72 hours post dose
Primary Part 2: Plasma PK parameter, ?z and t1/2 from predose up to 72 hours post dose
Secondary Part 1: QTcF changes from baseline The effect of coincidentally measured (time-matched) plasma concentrations of MIN-l0l on QTcF changes from Baseline. from predose up to 72 hours post dose
Secondary Part 1: Safety (AE reporting, safety laboratory parameters analysis, vital signs and 12 lead ECG assessments) Safety will be assessed through AE reporting, safety laboratory parameters analysis, vital signs and 12 lead ECG assessments 2 months 16 days
Secondary Part 2: Safety (AE reporting, safety laboratory parameters analysis, vital signs and 12 lead ECG assessments) Safety will be assessed through AE reporting, safety laboratory parameters analysis, vital signs and 12 lead ECG assessments 2 months 16 days
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1